The Indian Drug Manufacturers Association, a body of domestic drug makers, has moved the Delhi High Court against the government order banning 344 fixed dose combinations (FDCs). Filed last week with the Federation of Pharma Enterpreneurs, it is to be heard on Monday, say sources.
The associations argue these drugs, banned on the reasoning of irrationality, has been used by people across the country, based on prescription, for several decades and no major adverse reaction was reported.
The central government announced a ban on 344 FDCs on March 10, after a panel of experts said these lacked therapeutic effects and had health risks. Following this, at least 20 drug companies moved various high courts, seeking revocation of the decision.
On Tuesday, the high court here refused to give a stay on the government order, on a petition filed by the Federation of South Indian Pharmaceutical Manufacturers Association.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)